Orexin A in migraine: associations with clinical features of disease and comorbid disorders

Karpova MI, Serousova OV, Dolgushina AI, Vasilenko AF, Korotkova DG, Radaeva AA, Fastovets YuA. Orexin A in migraine: associations with clinical features of disease and comorbid disorders. Russian Journal of Pain. 2025;23(3):42‑51. (In Russ.)
https://doi.org/10.17116/pain20252303142

Подписка 2025 Российский журнал боли (Russian Journal of Pain)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study possible associations of migraine symptoms and comorbid disorders with serum orexin A.

MATERIAL AND METHODS

A cross-sectional single-stage study included 68 migraine patients with headache. Clinical and psychological state of patients was assessed. Serum orexin A was determined using enzyme-linked immunosorbent assay. The control group included 19 people. The results were analyzed using the SPSS Statistics software.

RESULTS

Migraine patients with abnormal fatigue accompanying paroxysmal headache had lower orexin A compared to other patients (medians 0.070 and 0.210 at p=0.042). Patients with skipped meals and low fluid intake as triggers had higher neuropeptide levels than those without such provocation (median 0.265 vs. 0.185, p=0.029; 0.535 vs. 0.190, p=0.017, respectively). Orexin A was lower in migraine patients with prodromal depressed mood (median 0.172 vs. 0.290 in migraineurs without such a feature, p=0.022). Orexin A was lower in patients with headache-associated abdominal pain (median 0.105 vs. 0.220 in those without such pain, p=0.023). We found an inverse relationship between orexin A concentration and severity of constipation as irritable bowel syndrome (rs=–0.257, p=0.035, N=68).

CONCLUSION

Altered orexin A concentrations may lead to imbalance of orexin-related mechanisms involved in regulation of nociception.

Keywords:

migraine

orexin A

triggers

prodrome

Authors:

Karpova M.I.

South-Ural State Medical University

ORCID: 0000-0001-5848-7235

Serousova O.V.

South Ural State Medical University

ORCID: 0000-0001-7362-5843

Dolgushina A.I.

South Urals State Medical University

ORCID: 0000-0003-2569-1699

Vasilenko A.F.

South Ural State Medical University

Scopus AuthorID: 50562028400
ORCID: 0000-0001-5799-7233

Korotkova D.G.

South Ural State Medical University

ORCID: 0000-0002-0875-1963

Radaeva A.A.

South Ural State Medical University

ORCID: 0009-0004-4942-1233

Fastovets Yu.A.

Chelyabinsk City Clinical Hospital No. 11

ORCID: 0009-0006-3642-7577

Received:

05.01.2025

Accepted:

17.03.2025

Close metadata

References:

GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology. 2017;16:877-897. https://doi.org/10.1016/S1474-4422(17)30299-5
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017 Apr;97(2):553-622. PMID: 28179394; PMCID: PMC5539409. https://doi.org/10.1152/physrev.00034.2015
Osipova VV, Filatova EG, Artemenko AR, Lebedeva ER, Azimova YuE, Latysheva NV, Sergeev AV, Amelin AV, Koreshkina MI, Skorobogatykh KV, Ekusheva EV, Naprienko MV, Isagulyan ED, Rachin AP, Danilov AlB, Kurushina OV. Diagnosis and treatment of migraine: Recommendations of the Russian experts. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1-2):28-42. (In Russ.). https://doi.org/10.17116/jnevro20171171228-42
Ayzenberg I, Katsarava Z, Sborowski A, Obermann M, Chernysh M, Osipova V, Tabeeva G, Steiner TJ. Headache yesterday in Russia: its prevalence and impact, and their application in estimating the national burden attributable to headache disorders. The Journal of Headache and Pain. 2015;16:7. https://doi.org/10.1186/1129-2377-16-7
Noseda R, Kainz V, Borsook D, Burstein R. Neurochemical Pathways That Converge on Thalamic Trigeminovascular Neurons: Potential Substrate for Modulation of Migraine by Sleep, Food Intake, Stress and Anxiety. PLoS One. 2014;9(8):e103929. https://doi.org/10.1371/journal.pone.0103929
Holland P, Goadsby PJ. The hypothalamic orexinergic system: pain and primary headaches. Headache. 2007;417(6):951-962. https://doi.org/10.1111/j.1526-4610.2007.00842.x
Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G. Hypothalamic Activation in Spontaneous Migraine Attacks. Headache. 2007;47:1418-1426. https://doi.org/10.1111/j.1526-4610.2007.00776.x
Stanyer EC, Hoffmann J, Holland PR. Orexins and primary headaches: an overview of the neurobiology and clinical impact. Expert Review of Neurotherapeutics. 2024 May;24(5):487-496. Epub 2024 Mar 22. PMID: 38517280; PMCID: PMC11034548. https://doi.org/10.1080/14737175.2024.2328728
Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699-710. https://doi.org/10.1038/s41582-018-0098-4
Kirchgessner AL. Orexins in the Brain-Gut Axis. Endocrine Reviews. 2002; 23(1):1-15. https://doi.org/10.1210/edrv.23.1.0454
Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. European Journal of Neuroscience. 2006;24(10):2825-2833. https://doi.org/10.1111/j.1460-9568.2006.05168.x
Okumura T, Takakusaki K. Role of orexin in central regulation of gastrointestinal functions. Journal of Gastroenterology. 2008;43(9):652-660. https://doi.org/10.1007/s00535-008-2218-1
Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of multiple physiological functions. British Journal of Pharmacology. 2013;171(2):332-350. https://doi.org/10.1111/bph.12415
Sarchielli P, Rainero I, Coppola F, Rossi C, Mancini ML, Pinessi L, Calabresi P. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28:714-722. https://doi.org/10.1111/j.1468-2982.2008.01566.x
Rainero I, Rubino E, Gallone S, Fenoglio P, Picci LR, Giobbe L, Ostacoli L, Pinessi L. Evidence for an association between migraine and the hypocretin receptor 1 gene. The Journal of Headache and Pain. 2011;12(2):193-199. https://doi.org/10.1007/s10194-011-0314-8
Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2014;35(5):379-388. https://doi.org/10.1177/0333102414544979
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808. https://doi.org/10.1177/0333102413485658
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88(1):41-52. PMID:11098098.
Svedlund J, Sjödi I, Dotevall G. GSRS — A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Digestive Diseases and Science. 1988;33(2):129-134. https://doi.org/10.1007/bf01535722
Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2013;137(1):232-241. https://doi.org/10.1093/brain/awt320
Schulte LH, May A. Of generators, networks and migraine attacks. Current Opinion in Neurology. 2017;30(3):241-245. https://doi.org/10.1097/wco.0000000000000441
Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(7):1987-1993. https://doi.org/10.1093/brain/aww097
Schulte LH, Allers A, May A. Hypothalamus as a mediator of chronic migraine. Neurology. 2017;88(21):2011-2016. https://doi.org/10.1212/wnl.0000000000003963
Lerebours F, Boulanouar K, Barège M, Denuelle M, Bonneville F, Payoux P, Larrue V, Fabre N. Functional connectivity of hypothalamus in chronic migraine with medication overuse. Cephalalgia. 2019 Jun;39(7):892-899. Epub 2019 Mar 05. PMID: 30836766. https://doi.org/10.1177/0333102419833087
Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol. 2021;27(44):7582-7596. https://doi.org/10.3748/wjg.v27.i44.7582
Pavlovic JM, Vieira JR, Lipton RB, Bond DS. Association between obesity and migraine in women. Current Pain and Headache Reports. 2017;21:41. https://doi.org/10.1007/s11916-017-0634-8
Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, Hargreaves R, Goadsby PJ. Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease. 2015;74:137-143. https://doi.org/10.1016/j.nbd.2014.10.022
Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M. Orexin directly excites orexin neurons through orexin 2 receptor. J Neurosci. 2010;30(38):12642-12652. https://doi.org/10.1523/JNEUROSCI.2120-10.2010
Kumar H, Dhamija K, Duggal A, Khwaja GA, Roshan S. Fatigue, chronic fatigue syndrome and migraine: intersecting the lines through a cross-sectional study in patients with episodic and chronic migraine. J Neurosci Rural Pract. 2023;14:424-431. https://doi.org/10.25259/jnrp_63_2022
Pavlovic JM, Buse DC, Sollars CM, Haut S, Lipton RB. Trigger factors and premonitory features of migraine attacks: summary of studies. Headache. 2014;25(10):1670-1679. https://doi.org/10.1111/head.12468
Okumura T, Nozu T. Role of brain orexin in the pathophysiology of functional gastrointestinal disorders. Journal of Gastroenterology and Hepatology. 2011;26(Suppl 3):61-66. https://doi.org/10.1111/j.1440-1746.2011.06626.x
Boeckxstaens G, Camilleri M, Sifrim D, Houghton LA, Elsenbruch S, Lindberg G, Azpiroz F, Parkman HP. Fundamentals of Neurogastroenterology: Physiology/Motility — Sensation. Gastroenterology. 2016;150(6):1292-1304.e2. https://doi.org/10.1053/j.gastro.2016.02.030